ESSENCE CS9 – TIMI 73b

ESSENCE CS9 TIMI 73b is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial in ~1320 patients to evaluate the safety and efficacy of olezarsen, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with either moderate hypertriglyceridemia and atherosclerotic cardiovascular disease (established or at increased risk for) or with severe hypertriglyceridemia.

CS9

ESSENCE CS9 – TIMI 73b on ClinicalTrials.gov

CONTACT US about ESSENCE CS9

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close